Disruptions in emotion, as well as impairments in cognition, are part of the daily struggle for individuals with mood disorders. Drug development teams are actively working to tackle these complex and interconnected symptoms.
Cogstate helps your team answer key drug development questions by providing highly sensitive and reliable digital cognitive tests, as well as tailored endpoint data quality programs for conventional assessments such as the MADRS, MINI, HAM-D, and HAM-A.
Please fill out the form below to download the fact sheet and learn more about we support Mood Disorder clinical trials globally.
